Stocks Health care OCUL
NASDAQ · Health careOcular Therapeutix, Inc (OCUL)
Ocular Therapeutix, Inc brought in $50.4M of revenue over the twelve months to September 30, 2026, down 9.7% from a year earlier. It posted a net loss of $326.8M. In fiscal 2025 capital spending exceeded operating cash flow by $216.9M. At September 30, 2026 it held $530.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about Ocular Therapeutix, Inc
- Net worth
- Ocular Therapeutix, Inc has a market value (market cap) of $1.5B at the latest share price, and shareholders' equity of $440.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $52M (-18.5% year on year), with a net loss of $265.9M. Over the 12 months to September 30, 2026: revenue $50.4M, net loss $326.8M.
- Cash flow
- In fiscal 2025 operations used $204.9M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Ocular Therapeutix, Inc's next report is expected around February 4, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Ocular Therapeutix, Inc does
Ocular Therapeutix, Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker OCUL.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $52M | -$265.9M | -$1.42 | -$216.9M |
| 2024 | $63.7M | -$193.5M | -$1.22 | -$136M |
| 2023 | $58.4M | -$80.7M | -$1.02 | -$76.3M |
| 2022 | $51.5M | -$71M | -$0.97 | -$63.3M |
| 2021 | $43.5M | -$6.6M | -$0.98 | -$66.7M |
| 2020 | $17.4M | -$155.6M | -$2.56 | -$54.4M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where OCUL ranks in Health care
Latest SEC filings
What Ocular Therapeutix, Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026
- November 9, 2026
- November 9, 2026Quarterly report 10-Q · period to September 30, 2026Revenue fell 11% to $12.9M versus the same quarter last year; diluted EPS -$0.42 versus -$0.38.
- November 9, 2026
- October 16, 2026
- August 3, 2026
- August 3, 2026Quarterly report 10-Q · period to June 30, 2026Revenue was flat at $13.5M versus the same quarter last year; diluted EPS -$0.35 versus -$0.39.
- August 3, 2026
- July 29, 2026Passive stake changed SCHEDULE 13G/A
- June 12, 2026
Insider trades
What the people running Ocular Therapeutix, Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $799.2K worth of shares in the last 90 days and bought none on the open market. Most of the selling (99%) was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 5, 2026 | Saroj NamrataChief Business Officer | Soldpre-planned (10b5-1) | 35,370 | $231.7K |
| October 8, 2026 | Anderman ToddChief Legal Officer | Soldpre-planned (10b5-1) | 11,984 | $87.4K |
| October 2, 2026 | Heier Jeffrey S.Chief Scientific Officer | Soldpre-planned (10b5-1) | 10,869 | $76.6K |
| October 2, 2026 | Kaiser PeterChief Development Officer | Soldpre-planned (10b5-1) | 9,990 | $70.4K |
| August 31, 2026 | Notman DonaldChief Operating Officer | Sold | 1,099 | $11.3K |
| August 25, 2026 | Dugel PravinSee Remarks, Director | Gave as a giftindirect | 50,092 | - |
| August 25, 2026 | Dugel PravinSee Remarks, Director | Gave as a giftindirect | 50,092 | - |
| August 24, 2026 | Dugel PravinSee Remarks, Director | Soldpre-planned (10b5-1) | 21,649 | $233.2K |
Who owns OCUL
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 15% | November 5, 2025 |
| Deep Track Capital, LP13G, passive with 2 related filers | 9.53% | May 15, 2026 |
| Avoro Capital Advisors LLC13G, passive with 1 related filers | 7.9% | November 14, 2024 |
| Summer Road LLC13G, passive | 5.7% | December 8, 2025 |
Largest institutional holders
Insiders
17 insiders reported holding 6,221,110 shares in total, about $41.1M at the last price.
| Holder | Shares |
|---|---|
| Dugel PravinSee Remarks, Director | 3,270,332744,903 held indirectly |
| Notman DonaldChief Operating Officer | 366,529 |
| Nayak SanjayChief Strategy Officer | 326,898 |
| Heier Jeffrey S.Chief Scientific Officer | 307,457 |
| Waheed NadiaChief Medical Officer | 300,079 |
| Lindstrom Richard L MdDirector | 260,933 |
| Kaiser PeterChief Development Officer | 254,388 |
| Saroj NamrataChief Business Officer | 220,522 |
| Meyers Steve LawrenceChief Commercial Officer | 217,628 |
| Anderman ToddChief Legal Officer | 140,484 |
Questions about OCUL
What does Ocular Therapeutix, Inc do?
Ocular Therapeutix, Inc is a company in the Health care sector, listed on NASDAQ as OCUL. Its shares trade on NASDAQ under the ticker OCUL.
What is Ocular Therapeutix, Inc's net worth?
Ocular Therapeutix, Inc has a market value (market cap) of $1.5B at the latest share price, and shareholders' equity of $440.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Ocular Therapeutix, Inc profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $326.8M on revenue of $50.4M.
How much revenue does Ocular Therapeutix, Inc make?
Over the twelve months to September 30, 2026 Ocular Therapeutix, Inc reported revenue of $50.4M. That is 9.7% less than a year earlier.
When did Ocular Therapeutix, Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
When is Ocular Therapeutix, Inc's next earnings report?
Ocular Therapeutix, Inc's next report is expected around February 4, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare OCUL with
Follow OCUL
Get an email when Ocular Therapeutix, Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Ocular Therapeutix, Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.